Agilent Technologies, Inc. (NYSE:A) Announces Quarterly Dividend of $0.26

Agilent Technologies, Inc. (NYSE:A) announced a quarterly dividend on Wednesday, November 19th. Shareholders of record on Tuesday, January 6th will be paid a dividend of 0.255 per share by the medical research company on Wednesday, January 28th. This represents a c) dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, January 6th. This is a 2.8% increase from Agilent Technologies’s previous quarterly dividend of $0.25.

Agilent Technologies has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 9 years. Agilent Technologies has a payout ratio of 16.4% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Agilent Technologies to earn $6.08 per share next year, which means the company should continue to be able to cover its $0.99 annual dividend with an expected future payout ratio of 16.3%.

Agilent Technologies Price Performance

A traded up $2.81 during midday trading on Thursday, hitting $147.21. The company had a trading volume of 114,352 shares, compared to its average volume of 1,884,655. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $153.84. The company has a market capitalization of $41.73 billion, a PE ratio of 34.54, a P/E/G ratio of 4.67 and a beta of 1.29. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The firm’s 50-day simple moving average is $138.72 and its 200-day simple moving average is $124.66.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the business earned $1.32 earnings per share. Agilent Technologies’s quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts predict that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total value of $1,873,500.00. Following the sale, the chief executive officer owned 33,448 shares in the company, valued at approximately $5,017,200. The trade was a 27.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company’s stock.

Institutional Trading of Agilent Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Flynn Zito Capital Management LLC grew its position in Agilent Technologies by 3.2% in the third quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 69 shares in the last quarter. Forum Financial Management LP grew its holdings in shares of Agilent Technologies by 2.5% in the 3rd quarter. Forum Financial Management LP now owns 2,921 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 70 shares in the last quarter. Gabelli Funds LLC increased its position in shares of Agilent Technologies by 1.1% in the third quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company’s stock valued at $850,000 after acquiring an additional 74 shares during the last quarter. Fiduciary Trust Co raised its holdings in Agilent Technologies by 1.6% during the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock worth $633,000 after acquiring an additional 77 shares in the last quarter. Finally, Wedmont Private Capital boosted its position in Agilent Technologies by 2.3% during the third quarter. Wedmont Private Capital now owns 3,630 shares of the medical research company’s stock valued at $503,000 after purchasing an additional 81 shares during the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.